Laura James
Concepts (571)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acetaminophen | 63 | 2025 | 279 | 12.350 |
Why?
| Analgesics, Non-Narcotic | 28 | 2025 | 117 | 5.220 |
Why?
| Drug Overdose | 17 | 2024 | 163 | 3.060 |
Why?
| Liver | 25 | 2025 | 1156 | 2.930 |
Why?
| Liver Failure, Acute | 13 | 2024 | 56 | 2.450 |
Why?
| Hepatocytes | 16 | 2018 | 190 | 2.370 |
Why?
| Liver Regeneration | 9 | 2019 | 47 | 1.890 |
Why?
| MicroRNAs | 5 | 2020 | 387 | 1.310 |
Why?
| Alanine Transaminase | 17 | 2023 | 122 | 1.250 |
Why?
| Male | 89 | 2025 | 26761 | 1.160 |
Why?
| Adolescent | 47 | 2025 | 6739 | 1.160 |
Why?
| Proton Pump Inhibitors | 7 | 2024 | 86 | 1.110 |
Why?
| Acetylcysteine | 13 | 2019 | 102 | 1.110 |
Why?
| Cytochrome P-450 CYP2E1 | 4 | 2020 | 111 | 1.110 |
Why?
| Mitochondria, Liver | 10 | 2015 | 69 | 1.080 |
Why?
| Child | 44 | 2025 | 7248 | 1.020 |
Why?
| Cytochrome P-450 CYP3A | 3 | 2020 | 78 | 1.010 |
Why?
| Oxidative Stress | 12 | 2023 | 807 | 1.010 |
Why?
| Humans | 107 | 2025 | 52483 | 0.950 |
Why?
| Chromatography, High Pressure Liquid | 10 | 2016 | 339 | 0.880 |
Why?
| Child, Preschool | 29 | 2024 | 4076 | 0.860 |
Why?
| Female | 68 | 2025 | 28171 | 0.840 |
Why?
| Cytokines | 8 | 2012 | 623 | 0.840 |
Why?
| Attitude | 2 | 2021 | 70 | 0.830 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2012 | 59 | 0.820 |
Why?
| Animals | 42 | 2025 | 13505 | 0.800 |
Why?
| Asthma | 4 | 2022 | 316 | 0.800 |
Why?
| Proteins | 4 | 2016 | 348 | 0.780 |
Why?
| Rape | 1 | 2022 | 16 | 0.770 |
Why?
| Vitamin D Deficiency | 1 | 2022 | 46 | 0.760 |
Why?
| Crime Victims | 1 | 2022 | 48 | 0.730 |
Why?
| Sex Offenses | 1 | 2022 | 79 | 0.700 |
Why?
| Health Facilities | 1 | 2021 | 40 | 0.690 |
Why?
| Mice | 30 | 2025 | 5949 | 0.680 |
Why?
| Cysteine | 7 | 2024 | 49 | 0.670 |
Why?
| Inflammation | 3 | 2020 | 641 | 0.660 |
Why?
| Naphthalenes | 9 | 2018 | 121 | 0.650 |
Why?
| Cytochrome P-450 CYP1A2 | 4 | 2020 | 39 | 0.650 |
Why?
| Indoles | 9 | 2018 | 278 | 0.650 |
Why?
| Vascular Endothelial Growth Factor A | 3 | 2011 | 182 | 0.640 |
Why?
| Health Services Accessibility | 2 | 2021 | 436 | 0.640 |
Why?
| Liver Diseases | 4 | 2023 | 83 | 0.640 |
Why?
| Bronchoconstriction | 1 | 2019 | 6 | 0.620 |
Why?
| Mitochondria | 2 | 2020 | 430 | 0.610 |
Why?
| 2-Pyridinylmethylsulfinylbenzimidazoles | 4 | 2018 | 18 | 0.590 |
Why?
| Aspartate Aminotransferases | 8 | 2015 | 49 | 0.590 |
Why?
| Bronchodilator Agents | 1 | 2019 | 77 | 0.570 |
Why?
| Radius | 1 | 2018 | 27 | 0.570 |
Why?
| Immunoassay | 1 | 2016 | 23 | 0.530 |
Why?
| Aryl Hydrocarbon Hydroxylases | 4 | 2014 | 74 | 0.530 |
Why?
| Serum | 1 | 2016 | 32 | 0.520 |
Why?
| Mice, Inbred C57BL | 16 | 2025 | 1884 | 0.520 |
Why?
| Imines | 4 | 2025 | 16 | 0.510 |
Why?
| Gastroesophageal Reflux | 4 | 2018 | 48 | 0.510 |
Why?
| Dose-Response Relationship, Drug | 12 | 2019 | 1378 | 0.510 |
Why?
| Benzoquinones | 4 | 2025 | 33 | 0.510 |
Why?
| Anti-Bacterial Agents | 6 | 2023 | 807 | 0.510 |
Why?
| Young Adult | 17 | 2023 | 4329 | 0.490 |
Why?
| Infant | 21 | 2022 | 3733 | 0.490 |
Why?
| Cystic Fibrosis | 1 | 2018 | 154 | 0.480 |
Why?
| Reactive Nitrogen Species | 3 | 2015 | 23 | 0.470 |
Why?
| Keratin-18 | 2 | 2021 | 14 | 0.470 |
Why?
| Proliferating Cell Nuclear Antigen | 4 | 2019 | 69 | 0.470 |
Why?
| Bile Acids and Salts | 1 | 2015 | 80 | 0.470 |
Why?
| HMGB1 Protein | 2 | 2021 | 21 | 0.470 |
Why?
| Lung | 1 | 2019 | 509 | 0.470 |
Why?
| Mass Spectrometry | 4 | 2014 | 292 | 0.460 |
Why?
| Tyrosine | 4 | 2007 | 87 | 0.460 |
Why?
| Mice, Inbred Strains | 7 | 2019 | 163 | 0.450 |
Why?
| Isoniazid | 1 | 2014 | 36 | 0.440 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 122 | 0.440 |
Why?
| Adult | 24 | 2025 | 14161 | 0.420 |
Why?
| Carnitine | 1 | 2014 | 68 | 0.420 |
Why?
| Disease Models, Animal | 7 | 2020 | 1478 | 0.420 |
Why?
| Autoantibodies | 1 | 2014 | 121 | 0.410 |
Why?
| Trifluoperazine | 1 | 2012 | 6 | 0.400 |
Why?
| Sensitivity and Specificity | 9 | 2016 | 891 | 0.390 |
Why?
| Viperidae | 1 | 2012 | 5 | 0.390 |
Why?
| Crotalid Venoms | 1 | 2012 | 8 | 0.390 |
Why?
| Antivenins | 1 | 2012 | 9 | 0.390 |
Why?
| Immunoglobulin Fragments | 1 | 2012 | 14 | 0.390 |
Why?
| Tomography, X-Ray Computed | 1 | 2018 | 1165 | 0.390 |
Why?
| Snake Bites | 1 | 2012 | 14 | 0.390 |
Why?
| Anti-Ulcer Agents | 3 | 2007 | 21 | 0.390 |
Why?
| Echinomycin | 1 | 2011 | 6 | 0.380 |
Why?
| Hepatitis, Viral, Human | 2 | 2024 | 8 | 0.380 |
Why?
| Prospective Studies | 12 | 2024 | 2481 | 0.360 |
Why?
| Cannabinoids | 5 | 2013 | 105 | 0.360 |
Why?
| Half-Life | 6 | 2019 | 88 | 0.360 |
Why?
| Spider Venoms | 1 | 2011 | 6 | 0.360 |
Why?
| Necrosis | 6 | 2019 | 176 | 0.360 |
Why?
| Enzyme Inhibitors | 5 | 2019 | 372 | 0.360 |
Why?
| Hypersensitivity | 1 | 2012 | 81 | 0.360 |
Why?
| Hospitalization | 4 | 2017 | 736 | 0.360 |
Why?
| Middle Aged | 18 | 2024 | 13028 | 0.360 |
Why?
| Phosphoric Diester Hydrolases | 1 | 2011 | 48 | 0.350 |
Why?
| Indocyanine Green | 1 | 2010 | 33 | 0.350 |
Why?
| Arkansas | 8 | 2025 | 2028 | 0.340 |
Why?
| Students | 2 | 2023 | 228 | 0.340 |
Why?
| Macrolides | 3 | 2022 | 17 | 0.330 |
Why?
| Models, Biological | 7 | 2024 | 735 | 0.320 |
Why?
| Methamphetamine | 3 | 2013 | 198 | 0.320 |
Why?
| Central Nervous System Stimulants | 3 | 2013 | 206 | 0.310 |
Why?
| Triazoles | 3 | 2022 | 115 | 0.310 |
Why?
| Metabolomics | 3 | 2015 | 150 | 0.300 |
Why?
| Protein Binding | 5 | 2017 | 667 | 0.300 |
Why?
| Homeostasis | 3 | 2020 | 201 | 0.290 |
Why?
| Chemokines | 2 | 2010 | 79 | 0.290 |
Why?
| Research Subjects | 2 | 2019 | 52 | 0.290 |
Why?
| Chemokine CCL2 | 2 | 2005 | 69 | 0.280 |
Why?
| Community-Based Participatory Research | 2 | 2021 | 203 | 0.280 |
Why?
| Glutathione | 5 | 2025 | 305 | 0.280 |
Why?
| Poisoning | 2 | 2006 | 21 | 0.270 |
Why?
| Area Under Curve | 8 | 2019 | 180 | 0.270 |
Why?
| Interleukin-6 | 3 | 2012 | 278 | 0.270 |
Why?
| Interleukin-8 | 3 | 2012 | 86 | 0.270 |
Why?
| Tandem Mass Spectrometry | 6 | 2018 | 251 | 0.260 |
Why?
| Pandemics | 2 | 2022 | 585 | 0.260 |
Why?
| Caustics | 1 | 2006 | 5 | 0.260 |
Why?
| Signal Transduction | 5 | 2019 | 1671 | 0.260 |
Why?
| Burns, Chemical | 1 | 2006 | 9 | 0.260 |
Why?
| Hypoxia-Inducible Factor 1 | 1 | 2006 | 3 | 0.260 |
Why?
| Cell Death | 4 | 2020 | 177 | 0.260 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 23 | 0.250 |
Why?
| Cross-Sectional Studies | 3 | 2022 | 1678 | 0.250 |
Why?
| Infant, Premature | 4 | 2016 | 333 | 0.240 |
Why?
| Antidotes | 4 | 2011 | 27 | 0.240 |
Why?
| Gene Expression Regulation | 3 | 2016 | 990 | 0.240 |
Why?
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2005 | 39 | 0.240 |
Why?
| Liver Function Tests | 2 | 2002 | 48 | 0.240 |
Why?
| Predictive Value of Tests | 5 | 2016 | 944 | 0.240 |
Why?
| Reactive Oxygen Species | 3 | 2015 | 421 | 0.240 |
Why?
| Peroxynitrous Acid | 2 | 2007 | 33 | 0.230 |
Why?
| Infant, Newborn | 10 | 2018 | 2867 | 0.230 |
Why?
| Cytochrome P-450 Enzyme System | 3 | 2015 | 191 | 0.230 |
Why?
| Universities | 2 | 2023 | 175 | 0.230 |
Why?
| Up-Regulation | 4 | 2018 | 454 | 0.220 |
Why?
| Immunohistochemistry | 3 | 2012 | 979 | 0.220 |
Why?
| Ion Channels | 1 | 2004 | 70 | 0.220 |
Why?
| Blood Pressure Monitoring, Ambulatory | 2 | 2015 | 34 | 0.220 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2024 | 53 | 0.220 |
Why?
| Gastric Acidity Determination | 1 | 2003 | 12 | 0.220 |
Why?
| Biotransformation | 4 | 2015 | 85 | 0.220 |
Why?
| Aminoglycosides | 1 | 2023 | 18 | 0.220 |
Why?
| Glucuronosyltransferase | 3 | 2017 | 122 | 0.210 |
Why?
| Chromatography, Liquid | 6 | 2018 | 240 | 0.210 |
Why?
| Diagnosis, Differential | 4 | 2024 | 1046 | 0.200 |
Why?
| Medication Adherence | 1 | 2024 | 133 | 0.200 |
Why?
| Administration, Oral | 7 | 2018 | 451 | 0.200 |
Why?
| Pilot Projects | 4 | 2021 | 721 | 0.200 |
Why?
| Membrane Glycoproteins | 1 | 2003 | 244 | 0.190 |
Why?
| Granzymes | 2 | 2020 | 11 | 0.190 |
Why?
| Designer Drugs | 2 | 2013 | 22 | 0.190 |
Why?
| Vitamins | 1 | 2022 | 64 | 0.190 |
Why?
| Digestive System | 1 | 2002 | 13 | 0.190 |
Why?
| Cell Line | 4 | 2017 | 1030 | 0.190 |
Why?
| Pneumonia, Bacterial | 1 | 2022 | 32 | 0.190 |
Why?
| Community-Acquired Infections | 1 | 2022 | 45 | 0.190 |
Why?
| Aged | 7 | 2024 | 10121 | 0.190 |
Why?
| Obesity | 2 | 2022 | 1162 | 0.190 |
Why?
| Vitamin D | 1 | 2022 | 90 | 0.190 |
Why?
| Gastrointestinal Agents | 1 | 2002 | 41 | 0.190 |
Why?
| Retrospective Studies | 9 | 2024 | 6607 | 0.190 |
Why?
| Phosphatidic Acids | 2 | 2019 | 8 | 0.190 |
Why?
| Parents | 1 | 2025 | 335 | 0.180 |
Why?
| Photography | 1 | 2021 | 31 | 0.180 |
Why?
| Microsomes, Liver | 4 | 2015 | 184 | 0.180 |
Why?
| United States | 7 | 2022 | 5192 | 0.180 |
Why?
| Anti-Infective Agents | 2 | 2013 | 107 | 0.180 |
Why?
| Sexual Behavior | 1 | 2022 | 128 | 0.180 |
Why?
| Metabolic Clearance Rate | 5 | 2018 | 69 | 0.180 |
Why?
| Dried Blood Spot Testing | 2 | 2018 | 5 | 0.180 |
Why?
| Oxidation-Reduction | 6 | 2023 | 326 | 0.180 |
Why?
| Gastrointestinal Diseases | 1 | 2002 | 125 | 0.170 |
Why?
| Bayes Theorem | 3 | 2012 | 121 | 0.170 |
Why?
| Healthcare Disparities | 1 | 2024 | 299 | 0.170 |
Why?
| Hydroxyurea | 1 | 2020 | 30 | 0.170 |
Why?
| Substance-Related Disorders | 3 | 2022 | 609 | 0.170 |
Why?
| Aged, 80 and over | 4 | 2021 | 3392 | 0.170 |
Why?
| Polymorphism, Genetic | 2 | 2018 | 185 | 0.160 |
Why?
| Heart Arrest | 1 | 2022 | 158 | 0.160 |
Why?
| Histamine H2 Antagonists | 3 | 2005 | 26 | 0.160 |
Why?
| Recombinant Proteins | 4 | 2018 | 483 | 0.160 |
Why?
| Brain | 3 | 2025 | 1323 | 0.160 |
Why?
| Statistics, Nonparametric | 2 | 2011 | 192 | 0.160 |
Why?
| Lipids | 1 | 2020 | 155 | 0.160 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 11 | 0.160 |
Why?
| Binding Sites | 2 | 2017 | 377 | 0.160 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2022 | 595 | 0.160 |
Why?
| Prothrombin Time | 3 | 2005 | 18 | 0.160 |
Why?
| Glycerol-3-Phosphate O-Acyltransferase | 1 | 2019 | 4 | 0.160 |
Why?
| Carbachol | 1 | 2019 | 26 | 0.160 |
Why?
| ortho-Aminobenzoates | 1 | 2019 | 6 | 0.160 |
Why?
| Mice, Knockout | 4 | 2011 | 879 | 0.160 |
Why?
| Time Factors | 5 | 2013 | 2968 | 0.160 |
Why?
| Stress, Physiological | 1 | 2020 | 183 | 0.150 |
Why?
| Respiratory Hypersensitivity | 1 | 2019 | 17 | 0.150 |
Why?
| Organ Culture Techniques | 1 | 2019 | 45 | 0.150 |
Why?
| Child, Hospitalized | 1 | 2019 | 31 | 0.150 |
Why?
| Liver Cirrhosis | 1 | 2021 | 240 | 0.150 |
Why?
| Drug Administration Schedule | 4 | 2021 | 374 | 0.150 |
Why?
| Disclosure | 1 | 2019 | 41 | 0.150 |
Why?
| Body Weight | 3 | 2018 | 523 | 0.150 |
Why?
| Case-Control Studies | 3 | 2018 | 1201 | 0.150 |
Why?
| Bacterial Infections | 2 | 2017 | 101 | 0.150 |
Why?
| Seroepidemiologic Studies | 3 | 2023 | 44 | 0.150 |
Why?
| Cannabidiol | 1 | 2019 | 43 | 0.150 |
Why?
| Research Personnel | 1 | 2019 | 71 | 0.150 |
Why?
| Oropharynx | 2 | 2009 | 13 | 0.150 |
Why?
| Ampicillin | 1 | 2018 | 6 | 0.150 |
Why?
| Hepatitis, Autoimmune | 1 | 2018 | 27 | 0.150 |
Why?
| Protein Biosynthesis | 2 | 2017 | 258 | 0.150 |
Why?
| HSP72 Heat-Shock Proteins | 1 | 2018 | 9 | 0.150 |
Why?
| Albuterol | 1 | 2019 | 57 | 0.150 |
Why?
| Information Dissemination | 1 | 2019 | 84 | 0.140 |
Why?
| Health Status Disparities | 1 | 2021 | 215 | 0.140 |
Why?
| Education, Nonprofessional | 1 | 2017 | 8 | 0.140 |
Why?
| Phosphatidate Phosphatase | 1 | 2018 | 23 | 0.140 |
Why?
| Human Experimentation | 1 | 2017 | 11 | 0.140 |
Why?
| Treatment Outcome | 6 | 2019 | 5422 | 0.140 |
Why?
| Mass Screening | 1 | 2021 | 357 | 0.140 |
Why?
| Sirtuin 1 | 1 | 2017 | 29 | 0.140 |
Why?
| Sulfonamides | 1 | 2019 | 133 | 0.140 |
Why?
| Teicoplanin | 1 | 2017 | 4 | 0.140 |
Why?
| Teaching Materials | 1 | 2017 | 31 | 0.140 |
Why?
| 3' Untranslated Regions | 1 | 2017 | 55 | 0.140 |
Why?
| Patient Participation | 1 | 2018 | 69 | 0.140 |
Why?
| Health Services Research | 1 | 2018 | 153 | 0.140 |
Why?
| Absorptiometry, Photon | 1 | 2018 | 162 | 0.140 |
Why?
| Rural Population | 2 | 2021 | 577 | 0.140 |
Why?
| Reading | 1 | 2017 | 73 | 0.140 |
Why?
| Severity of Illness Index | 3 | 2024 | 1026 | 0.140 |
Why?
| Substance Abuse Detection | 2 | 2022 | 89 | 0.140 |
Why?
| Genetic Predisposition to Disease | 1 | 2020 | 528 | 0.130 |
Why?
| Electrochemical Techniques | 1 | 2016 | 9 | 0.130 |
Why?
| Anthropometry | 2 | 2015 | 101 | 0.130 |
Why?
| Comprehension | 1 | 2017 | 113 | 0.130 |
Why?
| Nuclear Proteins | 1 | 2018 | 245 | 0.130 |
Why?
| Age Factors | 3 | 2015 | 1132 | 0.130 |
Why?
| Saliva | 1 | 2016 | 56 | 0.130 |
Why?
| Vitamin A | 1 | 2016 | 17 | 0.130 |
Why?
| Liver Failure | 1 | 2016 | 22 | 0.130 |
Why?
| Amphetamine | 2 | 2013 | 38 | 0.130 |
Why?
| Nitric Oxide Synthase Type I | 2 | 2015 | 11 | 0.130 |
Why?
| Injections, Intravenous | 3 | 2012 | 138 | 0.130 |
Why?
| Point-of-Care Systems | 1 | 2016 | 65 | 0.120 |
Why?
| Blood Proteins | 2 | 2006 | 85 | 0.120 |
Why?
| Caffeine | 1 | 2016 | 61 | 0.120 |
Why?
| Blood Pressure Monitors | 1 | 2015 | 10 | 0.120 |
Why?
| Taurodeoxycholic Acid | 1 | 2015 | 6 | 0.120 |
Why?
| Glycodeoxycholic Acid | 1 | 2015 | 6 | 0.120 |
Why?
| Glycochenodeoxycholic Acid | 1 | 2015 | 6 | 0.120 |
Why?
| Guanidines | 1 | 2015 | 29 | 0.120 |
Why?
| Biomedical Research | 1 | 2019 | 256 | 0.120 |
Why?
| Keratin-8 | 1 | 2015 | 3 | 0.120 |
Why?
| Styrene | 1 | 2015 | 9 | 0.120 |
Why?
| Bone Density | 1 | 2018 | 399 | 0.120 |
Why?
| Delayed-Action Preparations | 2 | 2012 | 55 | 0.120 |
Why?
| Prodrugs | 2 | 2012 | 35 | 0.120 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 72 | 0.120 |
Why?
| Solid Phase Extraction | 2 | 2013 | 14 | 0.120 |
Why?
| Tablets | 3 | 2013 | 31 | 0.120 |
Why?
| Breast Neoplasms | 1 | 2024 | 1212 | 0.120 |
Why?
| Cross-Over Studies | 2 | 2012 | 238 | 0.120 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2014 | 2 | 0.120 |
Why?
| Immunity, Innate | 1 | 2016 | 117 | 0.120 |
Why?
| Nitrates | 2 | 2011 | 31 | 0.120 |
Why?
| Administration, Intravenous | 3 | 2019 | 73 | 0.110 |
Why?
| Cells, Cultured | 4 | 2017 | 1567 | 0.110 |
Why?
| Famotidine | 2 | 2005 | 11 | 0.110 |
Why?
| Discriminant Analysis | 1 | 2014 | 27 | 0.110 |
Why?
| Least-Squares Analysis | 1 | 2014 | 44 | 0.110 |
Why?
| Environmental Pollutants | 1 | 2015 | 106 | 0.110 |
Why?
| Urinalysis | 1 | 2014 | 33 | 0.110 |
Why?
| Superoxide Dismutase | 2 | 2011 | 119 | 0.110 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2012 | 399 | 0.110 |
Why?
| Wounds, Stab | 1 | 2013 | 5 | 0.110 |
Why?
| Cannabis | 2 | 2019 | 150 | 0.110 |
Why?
| Cyclosporine | 2 | 2011 | 67 | 0.100 |
Why?
| Basal Ganglia | 1 | 2013 | 25 | 0.100 |
Why?
| Neck Injuries | 1 | 2013 | 21 | 0.100 |
Why?
| Fentanyl | 1 | 2014 | 41 | 0.100 |
Why?
| Benzoflavones | 1 | 2013 | 3 | 0.100 |
Why?
| Sulfaphenazole | 1 | 2013 | 4 | 0.100 |
Why?
| Nonlinear Dynamics | 2 | 2012 | 19 | 0.100 |
Why?
| Self-Injurious Behavior | 1 | 2013 | 30 | 0.100 |
Why?
| Kinetics | 4 | 2018 | 626 | 0.100 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2012 | 505 | 0.100 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2012 | 17 | 0.100 |
Why?
| Cohort Studies | 3 | 2019 | 1542 | 0.100 |
Why?
| Mycophenolic Acid | 1 | 2012 | 19 | 0.100 |
Why?
| Myoglobin | 1 | 2013 | 25 | 0.100 |
Why?
| Receptors, Phospholipase A2 | 1 | 2012 | 14 | 0.100 |
Why?
| Neurotoxicity Syndromes | 1 | 2013 | 46 | 0.100 |
Why?
| Indicators and Reagents | 1 | 2012 | 36 | 0.100 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 25 | 0.100 |
Why?
| Dinoprostone | 1 | 2012 | 49 | 0.100 |
Why?
| Permeability | 1 | 2012 | 66 | 0.100 |
Why?
| Flushing | 1 | 2012 | 5 | 0.100 |
Why?
| Piperacillin | 1 | 2012 | 23 | 0.100 |
Why?
| Fasting | 1 | 2012 | 75 | 0.100 |
Why?
| Immunoglobulin Fab Fragments | 1 | 2012 | 16 | 0.100 |
Why?
| Antibodies, Viral | 2 | 2023 | 109 | 0.100 |
Why?
| Blood Specimen Collection | 1 | 2012 | 35 | 0.100 |
Why?
| T-Lymphocytes | 1 | 2014 | 340 | 0.100 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 105 | 0.100 |
Why?
| Erythema | 1 | 2012 | 38 | 0.100 |
Why?
| Insulin | 1 | 2014 | 479 | 0.090 |
Why?
| Metronidazole | 1 | 2012 | 28 | 0.090 |
Why?
| Exanthema | 1 | 2012 | 31 | 0.090 |
Why?
| Pruritus | 1 | 2012 | 45 | 0.090 |
Why?
| Lipopolysaccharides | 1 | 2013 | 206 | 0.090 |
Why?
| Ketamine | 1 | 2012 | 59 | 0.090 |
Why?
| Cardiopulmonary Bypass | 1 | 2012 | 95 | 0.090 |
Why?
| Heart Septal Defects, Ventricular | 1 | 2012 | 45 | 0.090 |
Why?
| Vancomycin | 1 | 2012 | 85 | 0.090 |
Why?
| Neutropenia | 1 | 2012 | 115 | 0.090 |
Why?
| Sex Factors | 1 | 2014 | 727 | 0.090 |
Why?
| Cellulitis | 1 | 2011 | 10 | 0.090 |
Why?
| Receptor, Cannabinoid, CB1 | 1 | 2012 | 123 | 0.090 |
Why?
| Neuroprotective Agents | 1 | 2012 | 101 | 0.090 |
Why?
| Nitroimidazoles | 1 | 2011 | 16 | 0.090 |
Why?
| Anemia, Hemolytic | 1 | 2011 | 11 | 0.090 |
Why?
| Rhabdomyolysis | 1 | 2011 | 12 | 0.090 |
Why?
| Hair | 1 | 2011 | 29 | 0.090 |
Why?
| Hypertension | 2 | 2015 | 565 | 0.090 |
Why?
| Anti-Inflammatory Agents | 1 | 2012 | 166 | 0.090 |
Why?
| Coloring Agents | 1 | 2010 | 69 | 0.090 |
Why?
| Brain Injuries | 1 | 2012 | 159 | 0.090 |
Why?
| Muscular Diseases | 1 | 2011 | 63 | 0.090 |
Why?
| Kidney Transplantation | 1 | 2012 | 192 | 0.090 |
Why?
| Interleukin-10 | 2 | 2012 | 84 | 0.080 |
Why?
| Immunoblotting | 1 | 2010 | 116 | 0.080 |
Why?
| Liver Circulation | 1 | 2010 | 21 | 0.080 |
Why?
| Sodium Oxybate | 1 | 2009 | 11 | 0.080 |
Why?
| Butylene Glycols | 1 | 2009 | 14 | 0.080 |
Why?
| Coma | 1 | 2009 | 16 | 0.080 |
Why?
| Play and Playthings | 1 | 2009 | 14 | 0.080 |
Why?
| Kidney Diseases | 1 | 2012 | 220 | 0.080 |
Why?
| Linear Models | 2 | 2012 | 287 | 0.080 |
Why?
| Blood Pressure | 1 | 2012 | 537 | 0.080 |
Why?
| Databases as Topic | 1 | 2009 | 39 | 0.080 |
Why?
| Environmental Exposure | 1 | 2011 | 216 | 0.080 |
Why?
| Foreign Bodies | 1 | 2009 | 66 | 0.080 |
Why?
| Immunosuppressive Agents | 1 | 2011 | 243 | 0.080 |
Why?
| Blood Chemical Analysis | 1 | 2008 | 28 | 0.080 |
Why?
| Drug Compounding | 1 | 2008 | 28 | 0.080 |
Why?
| Incidence | 1 | 2012 | 1062 | 0.080 |
Why?
| Cesium | 1 | 2008 | 8 | 0.080 |
Why?
| Chlorides | 1 | 2008 | 46 | 0.070 |
Why?
| Registries | 2 | 2024 | 581 | 0.070 |
Why?
| Probability | 1 | 2008 | 172 | 0.070 |
Why?
| DNA | 1 | 2011 | 549 | 0.070 |
Why?
| Macrophages | 2 | 2017 | 379 | 0.070 |
Why?
| Analgesics, Opioid | 1 | 2014 | 590 | 0.070 |
Why?
| Chloroform | 1 | 2007 | 5 | 0.070 |
Why?
| Models, Statistical | 1 | 2009 | 230 | 0.070 |
Why?
| Free Radical Scavengers | 2 | 2011 | 25 | 0.070 |
Why?
| Magnetic Resonance Imaging | 2 | 2012 | 1546 | 0.070 |
Why?
| Infusions, Intravenous | 2 | 2023 | 220 | 0.070 |
Why?
| Acute Kidney Injury | 1 | 2011 | 319 | 0.070 |
Why?
| Sulfuric Acids | 1 | 2006 | 8 | 0.070 |
Why?
| Electrocardiography | 1 | 2008 | 268 | 0.070 |
Why?
| Aerobiosis | 1 | 2006 | 13 | 0.060 |
Why?
| Analysis of Variance | 1 | 2007 | 554 | 0.060 |
Why?
| Genotype | 3 | 2018 | 566 | 0.060 |
Why?
| Emergency Medicine | 1 | 2006 | 51 | 0.060 |
Why?
| Hepatitis C, Chronic | 2 | 2018 | 86 | 0.060 |
Why?
| Toxicity Tests | 1 | 2006 | 57 | 0.060 |
Why?
| Reproducibility of Results | 3 | 2015 | 1229 | 0.060 |
Why?
| Antioxidants | 2 | 2023 | 256 | 0.060 |
Why?
| Phosphorylation | 2 | 2019 | 528 | 0.060 |
Why?
| Cell Nucleus | 1 | 2006 | 187 | 0.060 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 235 | 0.060 |
Why?
| Mice, Transgenic | 2 | 2018 | 552 | 0.060 |
Why?
| Metabolic Detoxication, Phase II | 2 | 2017 | 11 | 0.060 |
Why?
| Mitochondrial Membrane Transport Proteins | 1 | 2004 | 18 | 0.060 |
Why?
| Child Abuse | 1 | 2006 | 140 | 0.060 |
Why?
| Receptors, Progesterone | 1 | 2024 | 66 | 0.060 |
Why?
| Kupffer Cells | 1 | 2003 | 12 | 0.050 |
Why?
| Computer Simulation | 2 | 2017 | 290 | 0.050 |
Why?
| Glutathione Disulfide | 1 | 2003 | 38 | 0.050 |
Why?
| Single-Blind Method | 2 | 2015 | 116 | 0.050 |
Why?
| Models, Chemical | 2 | 2015 | 66 | 0.050 |
Why?
| Risk Assessment | 1 | 2008 | 1327 | 0.050 |
Why?
| Superoxides | 1 | 2003 | 46 | 0.050 |
Why?
| Pyruvic Acid | 1 | 2023 | 21 | 0.050 |
Why?
| Papillomavirus Vaccines | 1 | 2025 | 70 | 0.050 |
Why?
| Receptors, Estrogen | 1 | 2024 | 131 | 0.050 |
Why?
| Alanine | 1 | 2023 | 44 | 0.050 |
Why?
| Omeprazole | 1 | 2003 | 16 | 0.050 |
Why?
| Ischemia | 1 | 2024 | 150 | 0.050 |
Why?
| Mixed Function Oxygenases | 1 | 2003 | 25 | 0.050 |
Why?
| Injections, Intraperitoneal | 1 | 2003 | 57 | 0.050 |
Why?
| Safety | 1 | 2003 | 79 | 0.050 |
Why?
| Immunoenzyme Techniques | 1 | 2003 | 137 | 0.050 |
Why?
| Prognosis | 3 | 2015 | 2099 | 0.050 |
Why?
| Hydrogen Peroxide | 1 | 2003 | 120 | 0.050 |
Why?
| Oxygen | 1 | 2006 | 336 | 0.050 |
Why?
| Radiographic Image Enhancement | 1 | 2003 | 29 | 0.050 |
Why?
| Genetic Variation | 1 | 2024 | 230 | 0.050 |
Why?
| Pediatrics | 1 | 2006 | 293 | 0.050 |
Why?
| Tibial Fractures | 1 | 2003 | 33 | 0.050 |
Why?
| Logistic Models | 2 | 2018 | 925 | 0.050 |
Why?
| Drug Interactions | 1 | 2003 | 206 | 0.050 |
Why?
| Molecular Structure | 2 | 2013 | 314 | 0.050 |
Why?
| Papillomavirus Infections | 1 | 2025 | 173 | 0.050 |
Why?
| Vaccination | 1 | 2025 | 298 | 0.050 |
Why?
| Membrane Potential, Mitochondrial | 2 | 2015 | 39 | 0.050 |
Why?
| Liver Transplantation | 1 | 2024 | 165 | 0.050 |
Why?
| Endothelium, Vascular | 1 | 2003 | 246 | 0.050 |
Why?
| Hydroxylation | 2 | 2012 | 62 | 0.050 |
Why?
| Neoplasms | 1 | 2012 | 1325 | 0.050 |
Why?
| Glutamate Dehydrogenase | 1 | 2021 | 16 | 0.050 |
Why?
| Death, Sudden, Cardiac | 1 | 2022 | 59 | 0.050 |
Why?
| Nitric Oxide | 1 | 2003 | 249 | 0.050 |
Why?
| Psychotropic Drugs | 1 | 2022 | 77 | 0.050 |
Why?
| Databases, Factual | 1 | 2024 | 706 | 0.040 |
Why?
| Uncertainty | 1 | 2021 | 44 | 0.040 |
Why?
| Longitudinal Studies | 1 | 2023 | 747 | 0.040 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 509 | 0.040 |
Why?
| Kidney Failure, Chronic | 1 | 2003 | 210 | 0.040 |
Why?
| Apoptosis | 1 | 2006 | 1119 | 0.040 |
Why?
| Gestational Age | 2 | 2012 | 417 | 0.040 |
Why?
| Anti-Asthmatic Agents | 1 | 2020 | 33 | 0.040 |
Why?
| Australia | 1 | 2019 | 89 | 0.040 |
Why?
| Decision Making | 1 | 2002 | 282 | 0.040 |
Why?
| Risk Factors | 3 | 2012 | 3889 | 0.040 |
Why?
| Research Design | 1 | 2021 | 359 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 150 | 0.040 |
Why?
| Tissue Distribution | 2 | 2013 | 171 | 0.040 |
Why?
| Hepatitis Viruses | 1 | 2018 | 2 | 0.040 |
Why?
| Qualitative Research | 1 | 2021 | 364 | 0.040 |
Why?
| beta Catenin | 1 | 2019 | 102 | 0.040 |
Why?
| Mallory Bodies | 1 | 2018 | 1 | 0.040 |
Why?
| Drug Dosage Calculations | 1 | 2018 | 11 | 0.040 |
Why?
| Metagenomics | 1 | 2018 | 46 | 0.040 |
Why?
| Acute-Phase Reaction | 1 | 2018 | 8 | 0.040 |
Why?
| DNA, Viral | 1 | 2018 | 137 | 0.040 |
Why?
| Pregnancy | 1 | 2025 | 2680 | 0.040 |
Why?
| RNA, Viral | 1 | 2018 | 127 | 0.040 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2018 | 80 | 0.040 |
Why?
| Ethics, Research | 1 | 2017 | 39 | 0.040 |
Why?
| Metabolic Networks and Pathways | 1 | 2018 | 93 | 0.040 |
Why?
| Metabolic Detoxication, Phase I | 1 | 2017 | 11 | 0.030 |
Why?
| Gas Chromatography-Mass Spectrometry | 2 | 2011 | 69 | 0.030 |
Why?
| MAP Kinase Signaling System | 1 | 2018 | 121 | 0.030 |
Why?
| Gene Frequency | 1 | 2017 | 98 | 0.030 |
Why?
| Glucuronides | 1 | 2017 | 48 | 0.030 |
Why?
| Rats | 2 | 2014 | 3220 | 0.030 |
Why?
| HEK293 Cells | 1 | 2017 | 229 | 0.030 |
Why?
| Communication | 1 | 2019 | 257 | 0.030 |
Why?
| Transfection | 1 | 2017 | 357 | 0.030 |
Why?
| Plant Extracts | 1 | 2019 | 194 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 182 | 0.030 |
Why?
| Residence Characteristics | 1 | 2017 | 159 | 0.030 |
Why?
| Liver Diseases, Alcoholic | 1 | 2016 | 35 | 0.030 |
Why?
| Oscillometry | 1 | 2015 | 9 | 0.030 |
Why?
| Sex Characteristics | 1 | 2017 | 198 | 0.030 |
Why?
| Health Literacy | 1 | 2017 | 132 | 0.030 |
Why?
| NAD | 1 | 2015 | 45 | 0.030 |
Why?
| Diastole | 1 | 2015 | 70 | 0.030 |
Why?
| Arm | 1 | 2015 | 47 | 0.030 |
Why?
| Systole | 1 | 2015 | 72 | 0.030 |
Why?
| Binding, Competitive | 1 | 2015 | 90 | 0.030 |
Why?
| Observer Variation | 1 | 2015 | 134 | 0.030 |
Why?
| Patient Safety | 1 | 2016 | 104 | 0.030 |
Why?
| Substrate Specificity | 1 | 2015 | 193 | 0.030 |
Why?
| Clinical Protocols | 1 | 2015 | 108 | 0.030 |
Why?
| Suramin | 1 | 2014 | 10 | 0.030 |
Why?
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2014 | 3 | 0.030 |
Why?
| Fas Ligand Protein | 1 | 2014 | 17 | 0.030 |
Why?
| Antigens, Ly | 1 | 2014 | 12 | 0.030 |
Why?
| Cell Proliferation | 1 | 2019 | 1023 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 185 | 0.030 |
Why?
| Islets of Langerhans | 1 | 2014 | 26 | 0.030 |
Why?
| Oxygen Consumption | 1 | 2015 | 198 | 0.030 |
Why?
| Glucose Tolerance Test | 1 | 2014 | 60 | 0.030 |
Why?
| Algorithms | 1 | 2018 | 672 | 0.030 |
Why?
| Gene Silencing | 1 | 2014 | 118 | 0.030 |
Why?
| Thiazolidinediones | 1 | 2014 | 83 | 0.030 |
Why?
| Biological Availability | 2 | 2005 | 108 | 0.030 |
Why?
| Pentanones | 1 | 2013 | 7 | 0.030 |
Why?
| Capsules | 1 | 2013 | 29 | 0.030 |
Why?
| Glutathione Transferase | 1 | 2014 | 174 | 0.030 |
Why?
| Powders | 1 | 2013 | 25 | 0.030 |
Why?
| Paper | 1 | 2013 | 16 | 0.030 |
Why?
| Methylamines | 1 | 2013 | 20 | 0.030 |
Why?
| Ethanol | 1 | 2016 | 342 | 0.030 |
Why?
| Body Temperature Regulation | 1 | 2013 | 30 | 0.030 |
Why?
| Benzodioxoles | 1 | 2013 | 43 | 0.030 |
Why?
| Pyrrolidines | 1 | 2013 | 69 | 0.030 |
Why?
| Hallucinogens | 1 | 2013 | 60 | 0.030 |
Why?
| Fatal Outcome | 1 | 2013 | 197 | 0.030 |
Why?
| Heterozygote | 1 | 2012 | 90 | 0.020 |
Why?
| Pyrans | 1 | 2012 | 16 | 0.020 |
Why?
| Drug Resistance | 1 | 2012 | 65 | 0.020 |
Why?
| Cell Survival | 1 | 2014 | 612 | 0.020 |
Why?
| Placebo Effect | 1 | 2012 | 16 | 0.020 |
Why?
| Amine Oxidase (Copper-Containing) | 1 | 2012 | 3 | 0.020 |
Why?
| Interleukin-3 | 1 | 2012 | 12 | 0.020 |
Why?
| Fever | 1 | 2013 | 112 | 0.020 |
Why?
| Calcitonin Gene-Related Peptide | 1 | 2012 | 24 | 0.020 |
Why?
| Prescription Drugs | 1 | 2012 | 41 | 0.020 |
Why?
| Intention to Treat Analysis | 1 | 2012 | 30 | 0.020 |
Why?
| Histamine | 1 | 2012 | 25 | 0.020 |
Why?
| Protein Precursors | 1 | 2012 | 42 | 0.020 |
Why?
| Calcitonin | 1 | 2012 | 30 | 0.020 |
Why?
| Glucose | 1 | 2014 | 355 | 0.020 |
Why?
| Insurance, Health, Reimbursement | 1 | 2012 | 24 | 0.020 |
Why?
| Dopamine | 1 | 2013 | 173 | 0.020 |
Why?
| Spectroscopy, Near-Infrared | 1 | 2012 | 53 | 0.020 |
Why?
| Disease Progression | 1 | 2015 | 871 | 0.020 |
Why?
| Population | 1 | 2012 | 8 | 0.020 |
Why?
| Office Visits | 1 | 2012 | 45 | 0.020 |
Why?
| Genetic Association Studies | 1 | 2012 | 122 | 0.020 |
Why?
| Ligands | 1 | 2012 | 206 | 0.020 |
Why?
| Hyperthermia, Induced | 1 | 2013 | 120 | 0.020 |
Why?
| Expectorants | 1 | 2011 | 14 | 0.020 |
Why?
| Risk | 1 | 2012 | 316 | 0.020 |
Why?
| Central Nervous System | 1 | 2012 | 76 | 0.020 |
Why?
| Glucuronic Acid | 1 | 2011 | 11 | 0.020 |
Why?
| Creatinine | 1 | 2012 | 150 | 0.020 |
Why?
| Microsomes | 1 | 2011 | 35 | 0.020 |
Why?
| Monte Carlo Method | 1 | 2012 | 87 | 0.020 |
Why?
| Deuterium | 1 | 2011 | 46 | 0.020 |
Why?
| Statistics as Topic | 1 | 2011 | 87 | 0.020 |
Why?
| ROC Curve | 1 | 2012 | 253 | 0.020 |
Why?
| Reference Standards | 1 | 2011 | 54 | 0.020 |
Why?
| Birth Weight | 1 | 2012 | 125 | 0.020 |
Why?
| Syndrome | 1 | 2012 | 247 | 0.020 |
Why?
| Cytoplasm | 1 | 2011 | 94 | 0.020 |
Why?
| Forensic Toxicology | 1 | 2011 | 4 | 0.020 |
Why?
| Muscular Dystrophies | 1 | 2011 | 14 | 0.020 |
Why?
| Hair Color | 1 | 2011 | 10 | 0.020 |
Why?
| Spinal Muscular Atrophies of Childhood | 1 | 2011 | 9 | 0.020 |
Why?
| Glucuronidase | 1 | 2011 | 47 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2012 | 155 | 0.020 |
Why?
| Crime | 1 | 2011 | 27 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2012 | 591 | 0.020 |
Why?
| Protein Isoforms | 1 | 2011 | 123 | 0.020 |
Why?
| Staining and Labeling | 1 | 2011 | 97 | 0.020 |
Why?
| Transaminases | 1 | 2011 | 11 | 0.020 |
Why?
| Forecasting | 1 | 2012 | 154 | 0.020 |
Why?
| Bilirubin | 1 | 2011 | 43 | 0.020 |
Why?
| Intensive Care Units | 1 | 2012 | 243 | 0.020 |
Why?
| Blotting, Western | 1 | 2011 | 590 | 0.020 |
Why?
| Intestines | 1 | 2011 | 154 | 0.020 |
Why?
| Double-Blind Method | 1 | 2012 | 713 | 0.020 |
Why?
| Child Development | 1 | 2012 | 200 | 0.020 |
Why?
| Intensive Care Units, Pediatric | 1 | 2011 | 179 | 0.020 |
Why?
| Intestinal Mucosa | 1 | 2011 | 224 | 0.020 |
Why?
| Body Mass Index | 1 | 2013 | 689 | 0.020 |
Why?
| Suction | 1 | 2009 | 24 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2013 | 1563 | 0.020 |
Why?
| Alcohol Drinking | 1 | 2011 | 237 | 0.020 |
Why?
| Eating | 1 | 2009 | 159 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2011 | 467 | 0.020 |
Why?
| Kidney | 1 | 2013 | 707 | 0.020 |
Why?
| Survival Rate | 1 | 2011 | 945 | 0.020 |
Why?
| Alcoholism | 1 | 2011 | 239 | 0.020 |
Why?
| Nitric Oxide Synthase | 1 | 2007 | 62 | 0.020 |
Why?
| Muscle, Skeletal | 1 | 2013 | 804 | 0.020 |
Why?
| Carcinoma, Hepatocellular | 1 | 2008 | 202 | 0.020 |
Why?
| Liver Neoplasms | 1 | 2008 | 333 | 0.010 |
Why?
| Follow-Up Studies | 1 | 2009 | 2279 | 0.010 |
Why?
| Electrophoresis, Gel, Pulsed-Field | 1 | 2003 | 28 | 0.010 |
Why?
| Specialization | 1 | 2003 | 49 | 0.010 |
Why?
| Medicine | 1 | 2003 | 54 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 2003 | 461 | 0.010 |
Why?
| Endopeptidases | 1 | 2002 | 66 | 0.010 |
Why?
|
|
James's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|